SimianX AI LogoSimianX AI

Record mula sa primary source

Decision-gradeTopline na resulta

Isiniksik ng Vaxcyte ang topline readout ng VAX-31 OPUS-1 sa katapusan ng Oktubre 2026

The company narrowed its prior Q4 2026 guidance to a specific end-of-October 2026 target for topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 pivotal trial. The announcement also disclosed the appointments of a new Chief Medical Officer and Chief Legal Officer ahead of the planned BLA submission.

Mahahalagang fact

Na-file
Set 3, 2026, 08:18 PM
Kaganapan
Topline na resulta
Direksyon
Neutral
Kumpanya
PCVXVaxcyte
Asset
VAX-31
Pinagmulan
SEC 8-K
Kumpiyansa
May source

Sipi mula sa source

EX-99.1 2 a20260831-8xkxpressrelea.htm EX-99.1 a20260831-8xkxpressrelea Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026 SAN CARLOS, Calif., September 3, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovati

SEC 8-K

Higit pa tungkol sa asset na ito